SEHK:2096Pharmaceuticals
Simcere Pharmaceutical Group (SEHK:2096) Margin Rebound Challenges Long Term Earnings Skepticism
Simcere Pharmaceutical Group (SEHK:2096) has reported its FY 2025 first half results with revenue of C¥3.6b and basic EPS of C¥0.25, setting a clear marker for how the year is shaping up. The company has seen revenue move from C¥3.1b in 1H 2024 to C¥3.5b in 2H 2024 and then to C¥3.6b in 1H 2025. Basic EPS progressed from C¥0.18 in 1H 2024 to C¥0.11 in 2H 2024 and then to C¥0.25 in the latest period, while trailing net margins sit at 17.4%, giving investors more detail on the recent...